			(Month/Day/Yea	r) if any (Month/Day/Year)	Code (Instr. 8) Code V		5) Amount (A) or (D) P		Price	Owned Following Reported Transaction(s) (Instr. 3 and 4)	(I) (Instr. 4)	Ownership (Instr. 4)		
Date				2A. Deemed Execution Date,	3. Transaction		4. Securities A Disposed Of (5. Amount of Securities Beneficially	6. Ownership Form: Direct (D) or Indirect	of Indirect		
		Table I - Nor	n-Derivative	e Securities Acq	uired	, Dis	posed of, o	or Ben	eficially	y Owned				
(City)	(State)	(Zip)												
SOUTH SAN FRANCISCO CA 94080								X	X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(Street)				If Amendment, Date c	of Origina	al File	d (Month/Day/`	Line)						
285 EAST GF	AND AVENU	Е												
C/O UNITY BIOTECHNOLOGY, INC.				/13/2020					Chief Medical Officer					
(Last) (First) (Middle)				Date of Earliest Trans	action (Month	/Day/Year)	X	Director 10% Owner					
Dananberg Jamie				nity Biotechno	<u>logy,</u>	<u>Inc.</u>	[UBX]							
1. Name and Address of Reporting Person*			2.1	2. Issuer Name and Ticker or Trading Symbol Unity Biotechnology, Inc. [UBX]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
Section 16. Form obligations may c Instruction 1(b).	4 or Form 5	Filed pursu or S	uant to Section 16(a) of Section 30(h) of the Inv		Estimated average burden hours per response: 0.5									
Check this box if	no longer subject to		OF CHANGES	S IN E	BEN	EFICIAL	NERSH		OMB Number: 3235-0287					
				Washingt	on, D.C	. 2054	9			OMB APPROVAL				
	RM 4	UNITED	STATES	SECURITIES	S ANI	DE	XCHANG	E CC	OMMIS	SION				
SEC Form 4														

Common Stock, \$0.0001 par value 09/13/2				2020				Α	240,000	1)	A \$ 0.	00 692	,219(1)(2)	D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Represents Restricted Stock Units ("RSUs") one-third of which vests on September 13, 2021 with the remaining RSUs vesting in equal quarterly installments over a two year period thereafter. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

2. Includes RSUs which vest over time measured from the grant date.

Remarks:

<u>/s/ Tamara L. Tompkins,</u> <u>Attorney-in-Fact for Jamie</u> <u>Dananberg</u>

09/15/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.